

Arlene Chan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8203177/publications.pdf>

Version: 2024-02-01

50
papers

7,478
citations

471061

17
h-index

214527

47
g-index

51
all docs

51
docs citations

51
times ranked

8154
citing authors

#	ARTICLE	IF	CITATIONS
1	Adjuvant Trastuzumab in HER2-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2011, 365, 1273-1283.	13.9	2,254
2	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1738-1748.	13.9	1,390
3	Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer. <i>Journal of Clinical Oncology</i> , 2010, 28, 3239-3247.	0.8	812
4	A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 533-543.	1.1	732
5	Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1688-1700.	5.1	451
6	Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2016, 17, 367-377.	5.1	444
7	Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 212-222.	5.1	169
8	Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 60-72.	5.1	161
9	Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarchHER): a randomised, open-label, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 763-775.	5.1	144
10	Final Efficacy Results of Neratinib in HER2-positive Hormone Receptor-positive Early-stage Breast Cancer From the Phase III ExteNET Trial. <i>Clinical Breast Cancer</i> , 2021, 21, 80-91.e7.	1.1	140
11	Phase III Study of Doxorubicin/Cyclophosphamide With Concomitant Versus Sequential Docetaxel As Adjuvant Treatment in Patients With Human Epidermal Growth Factor Receptor 2â€“Normal, Node-Positive Breast Cancer: BCIRC-005 Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 3877-3884.	0.8	135
12	Breast cancer bone metastases: pathogenesis and therapeutic targets. <i>International Journal of Biochemistry and Cell Biology</i> , 2018, 96, 63-78.	1.2	133
13	A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptorâ€“Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5310-5319.	3.2	102
14	Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSCG-42/AFT-05/BIG-14-03). <i>Journal of Clinical Oncology</i> , 2022, 40, 282-293.	0.8	88
15	Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness. <i>Therapeutic Advances in Medical Oncology</i> , 2016, 8, 339-350.	1.4	30
16	The role of pigment epithelium-derived factor in protecting against cellular stress. <i>Free Radical Research</i> , 2019, 53, 1166-1180.	1.5	23
17	A retrospective study investigating the rate of HER2 discordance between primary breast carcinoma and locoregional or metastatic disease. <i>BMC Cancer</i> , 2012, 12, 555.	1.1	21
18	Prevalence of Excessive Tearing in Women With Early Breast Cancer Receiving Adjuvant Docetaxel-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2013, 31, 2123-2127.	0.8	20

#	ARTICLE	IF	CITATIONS
19	Pigment epithelium-derived factor regulation of neuronal and stem cell fate. <i>Experimental Cell Research</i> , 2020, 389, 111891.	1.2	19
20	A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 106-115.	3.2	18
21	PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial. <i>Breast Cancer Research</i> , 2019, 21, 39.	2.2	17
22	Subxiphoid partial pericardiectomy with or without sclerosant instillation in the treatment of symptomatic pericardial effusions in patients with malignancy. <i>Cancer</i> , 1991, 68, 1021-1025.	2.0	16
23	Efficacy of scalp cooling in reducing alopecia in early breast cancer patients receiving contemporary chemotherapy regimens. <i>Breast</i> , 2018, 41, 127-132.	0.9	15
24	Reporting of myelotoxicity associated with emerging regimens for the treatment of selected solid tumors. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 81, 136-150.	2.0	14
25	Neratinib after trastuzumab in patients with HER2-positive breast cancer – Author's reply. <i>Lancet Oncology</i> , 2016, 17, e176-e177.	5.1	12
26	Compliance with multidisciplinary team meeting management recommendations. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 337-342.	0.7	12
27	Psychosocial consequences in offspring of women with breast cancer. <i>Psycho-Oncology</i> , 2020, 29, 517-524.	1.0	10
28	Pigment Epithelium-Derived Factor and Sex Hormone-Responsive Cancers. <i>Cancers</i> , 2020, 12, 3483.	1.7	10
29	Utilisation of primary and secondary G-CSF prophylaxis enables maintenance of optimal dose delivery of standard adjuvant chemotherapy for early breast cancer: An analysis of 1655 patients. <i>Breast</i> , 2014, 23, 676-682.	0.9	9
30	Drug induced vitiligo-like depigmentation from a CDK 4/6 inhibitor. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, .	0.7	9
31	Neratinib after trastuzumab-based adjuvant therapy in patients from Asia with early stage HER2-positive breast cancer. <i>Future Oncology</i> , 2019, 15, 2489-2501.	1.1	8
32	Male Breast Cancer in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, e57-e62.	0.7	8
33	Bone Health Outcomes from the International, Multicenter, Randomized, Phase 3, Placebo-Controlled D-CARE Study Assessing Adjuvant Denosumab in Early Breast Cancer. <i>Advances in Therapy</i> , 2021, 38, 4569-4580.	1.3	7
34	Randomized phase II placebo-controlled study to evaluate the efficacy of topical pure emu oil for joint pain related to adjuvant aromatase inhibitor use in postmenopausal women with early breast cancer: JUST (Joints Under Study). <i>Supportive Care in Cancer</i> , 2017, 25, 3785-3791.	1.0	6
35	Phase II, open-label trial of lapatinib and vinorelbine in women with previously treated HER2-positive metastatic breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2014, 10, 368-375.	0.7	5
36	A review of the importance of immune responses in luminal B breast cancer. <i>Oncolmmunology</i> , 2017, 6, e1282590.	2.1	5

#	ARTICLE	IF	CITATIONS
37	Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer. <i>Anticancer Research</i> , 2013, 33, 2657-64.	0.5	5
38	TILs in metastatic breast cancer—no surprises, but more questions. <i>Lancet Oncology</i> , The, 2017, 18, 5-6.	5.1	4
39	Code of practice needed for samples donated by trial participants. <i>Lancet Oncology</i> , The, 2022, 23, e89-e90.	5.1	4
40	A multicenter audit of the incidence of febrile neutropenia and neutropenia associated with docetaxel and cyclophosphamide (TC) chemotherapy for early breast cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1079-1079.	0.8	3
41	Preoperative taxane-based chemotherapy in a standardized protocol for locally advanced breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2012, 8, 62-70.	0.7	2
42	Adjuvant denosumab in early breast cancer — Authors' reply. <i>Lancet Oncology</i> , The, 2020, 21, e125.	5.1	2
43	Incorporation of eribulin in the systemic treatment of metastatic breast cancer patients in Australia. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2022, 18, 201-208.	0.7	2
44	Three-arm randomized phase II study evaluating oral vinorelbine plus capecitabine versus paclitaxel plus gemcitabine versus docetaxel plus gemcitabine as first-line chemotherapy in patients with metastatic breast cancer: Final results (NorCap-CA223 trial). <i>Journal of Clinical Oncology</i> , 2014, 32, 1044-1044.	0.8	2
45	Quality-Adjusted Survival with Ribociclib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women with HR±HER2~ Advanced Breast Cancer in the MONALEESA-3 Trial. <i>Clinical Breast Cancer</i> , 2022, 22, 326-335.	1.1	2
46	Lack of efficacy of adjuvant lapatinib in HER2-negative breast cancer (HER2~ve BC): Analysis of patients in the TEACH trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 628-628.	0.8	1
47	BreastSurgANZ members recommendations for adjuvant systemic treatment and patient compliance in Australian breast cancer patients. <i>ANZ Journal of Surgery</i> , 2021, 91, 2418-2424.	0.3	0
48	Denosumab versus placebo as adjuvant treatment for women with early-stage breast cancer at high risk of disease recurrence (D-CARE): An international, placebo-controlled, randomized, double-blind phase III clinical trial. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS662-TPS662.	0.8	0
49	Developing and evaluation of a new clinicopathologic response index after neoadjuvant chemotherapy as a predictor of clinical outcomes in locally advanced breast cancers. <i>Journal of Clinical Oncology</i> , 2014, 32, 1083-1083.	0.8	0
50	Trastuzumab biosimilar in early breast cancer setting: will there be direct patient benefits?. <i>Chinese Clinical Oncology</i> , 2017, 6, 55-55.	0.4	0